ArticlePloS one2024
Global antimicrobial resistance and use surveillance system (GLASS 2022): Investigating the relationship between antimicrobial resistance and antimicrobial consumption data across the participating countries.
Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
127 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pooled it
- Expression of multidrug efflux pump gene acrAB in Escherichia coli: a systematic review and meta analysis.BMC infectious diseases · 2025Pooled it
- Population Pharmacokinetics of Tigecycline and Implications for Individualized Therapy Optimization: A Systematic Review.Drug design, development and therapy · 2025Pooled it
- Shiga Toxin-ProducingAntibiotics (Basel, Switzerland) · 2026Review
- Microbiological Profile and Antimicrobial Resistance Patterns of Pleural Fluid Isolates in a Tertiary Care Setting in Lahore, Pakistan.Molecular biotechnology · 2026Article
- A comprehensive AMR genotype-phenotype database (CABBAGE).Nucleic acids research · 2026Article
- Adaptive Evolution in Aminoacyl-tRNA Synthetases Drives Antibiotic Tolerance and Resistance in Clinical Klebsiella pneumoniae Isolates.Molecular biotechnology · 2026Article
- Microbiome Profiling and Antimicrobial Efficacy of a Novel Silver-Nanoparticle Hydrogel Dressing Against Clinical Isolates From Paediatric Burn Wounds.MicrobiologyOpen · 2026Article
- Shift of antibiotic resistance after the COVID-19 pandemic: results from the INVIFAR Network.JAC-antimicrobial resistance · 2026Article
- Article
- Formulation-Level Tolerability of Repeated Drinking-Water Administration of a Commercial Multi-Component Bacteriophage Product in Ross 308 Broiler Chickens: A Pilot 27-Day Dose-Escalation Study.Veterinary sciences · 2026Article
- The Pharmacology of Bacterial Persistence: From Antibiotic Tolerance to Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2026Review
- Knowledge, Attitudes, and Practices Related to Antibiotic Use and Antibiotic Resistance Among Adults in Communities of Montserrado County, Liberia: A Household-Based Cross-Sectional Study.Antibiotics (Basel, Switzerland) · 2026Article
- Bacteriophage Lysins as Programmable Antimicrobials: Mechanisms, Engineering, and Translational Advances.Probiotics and antimicrobial proteins · 2026Review
- Duplex Recombinase Polymerase Amplification-Lateral Flow Assay for Rapid Visual Detection of Critical Antibiotic Resistance Genes in Escherichia coli and Klebsiella pneumoniae From Positive Blood Cultures.Journal of clinical laboratory analysis · 2026Article
- Prevalence of antibiotic residues in commercial poultry feed and meat from industrial and backyard poultry in Iquitos, Perú.IJID one health · 2026Article
- Antimicrobial quinoline triazoles: synthesis, docking, and dynamic simulation studies against biofilm-associated infections.Molecular diversity · 2026Article
- Antimicrobial resistance in Palestine: Emerging hotspots and trends from a 4-year hospital-based study.IJID regions · 2026Article
- Comprehensive Evaluation of Uropathogens' AMR in a Romanian Tertiary Center: Male vs. Female Comparison.Microorganisms · 2026Article
- Microbiological Profile and Antimicrobial Resistance Patterns in an Intensive Care Unit: Emphasis on ESKAPE Pathogens.Antibiotics (Basel, Switzerland) · 2026Article
67 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For the first time since 2015, the World Health Organization's (WHO) global Antimicrobial Resistance and Use Surveillance (GLASS) featured both global reports for antimicrobial resistance (AMR) and antimicrobial consumption (AMC) data in its annual reports. In this study we investigated the relationship of AMR with AMC within participating countries reported in the GLASS 2022 report. Our analysis found a statistically significant correlation between beta-lactam/cephalosporin and fluoroquinolones consumption and AMR to these antimicrobials associated with bloodstream E. coli and Klebsiella pneumoniae among the participating countries (P<0.05). We observed that for every 1 unit increase in defined daily dose DDD of beta-lactam/cephalosporins and quinolone consumptions among the countries, increased the recoveries of bloodstream-associated beta-lactam/cephalosporins-resistant E. coli/Klebsiella spp. by 11-22% and quinolone-resistant E. coli/Klebsiella spp. by 31-40%. When we compared the antimicrobial consumptions between the antimicrobial ATC (Alphanumeric codes developed by WHO) groups and countries, we observed a statistically significant higher daily consumption of beta-lactam-penicillins (J01C, DDD difference range: 5.23-8.13) and cephalosporins (J01D, DDD difference range: 2.57-5.13) compared to other antimicrobial groups among the countries (adjusted for multiple comparisons using Tukey's method). Between the participating countries, we observed a statistically significant higher daily consumption of antimicrobial groups in Iran (DDD difference range: 3.63-4.84) and Uganda (DDD difference range: 3.79-5.01) compared to other participating countries (adjusted for multiple comparisons using Tukey's method). Understanding AMC and how it relates to AMR at the global scale is critical in the global AMR policy development and implementation of global antimicrobial stewardship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.